We are live on ! Find out more
VTGN icon

VistaGen Therapeutics

74 hedge funds and large institutions have $227M invested in VistaGen Therapeutics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 28 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

530% more capital inflows, than outflows

Capital inflows: $104M | Capital outflows: $16.6M

460% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 5

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

42% more funds holding

Funds holding: 52 → 74 (+22)

24.79% more ownership

Funds ownership: 48.89% → 73.68% (+25%)

Holders
74
Holders Change
+22
Holders Change %
+42.31%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
32
Increased
28
Reduced
5
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VTGN Hedge Fund Activity: Q1 2021 in Review

74 of the 5,715 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2021, worth a combined $227M — up 74% from $131M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new VTGN positions and 10 closed out — a net gain of 22 holders — while 28 added to existing stakes and 5 trimmed.

The largest buyer was NEA Management Company, adding an estimated $15.4M. The largest seller was Asymmetry Capital Management, exiting entirely with an estimated $4.34M sold.

  • 74 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2021, up from 52 in Q4 2020.
  • Funds reported $227M of VistaGen Therapeutics stock for Q1 2021, up 74% quarter-over-quarter.
  • 32 funds opened new VistaGen Therapeutics positions in Q1 2021 and 10 closed out, a net change of +22 holders.
  • The largest VistaGen Therapeutics buyer in Q1 2021 was NEA Management Company, an estimated $15.4M added.
  • The largest VistaGen Therapeutics seller in Q1 2021 was Asymmetry Capital Management, an estimated $4.34M sold.

Based on aggregated 13F filings for Q1 2021.